MCID: PDT021
MIFTS: 35

Pediatric Osteosarcoma

Categories: Bone diseases, Cancer diseases

Aliases & Classifications for Pediatric Osteosarcoma

MalaCards integrated aliases for Pediatric Osteosarcoma:

Name: Pediatric Osteosarcoma 12 15
Childhood Osteosarcoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:3361
NCIt 50 C6585
UMLS 73 C1332986

Summaries for Pediatric Osteosarcoma

MalaCards based summary : Pediatric Osteosarcoma, also known as childhood osteosarcoma, is related to methotrexate toxicity or dose selection and myelomeningocele. An important gene associated with Pediatric Osteosarcoma is SLC19A1 (Solute Carrier Family 19 Member 1), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Selenium Micronutrient Network. The drugs Denosumab and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Pediatric Osteosarcoma

Diseases related to Pediatric Osteosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
# Related Disease Score Top Affiliating Genes
1 methotrexate toxicity or dose selection 10.1 MTHFR SLC19A1
2 myelomeningocele 10.1 MTHFR SLC19A1
3 transcobalamin ii deficiency 10.1 DHFR MTHFR
4 acute lymphoblastic leukemia, childhood 10.1 MTHFR SLC19A1
5 homocysteinemia 10.0 MTHFR SLC19A1
6 acute lymphocytic leukemia 10.0 MTHFR SLC19A1
7 sarcoma 10.0
8 megaloblastic anemia 9.9 DHFR MTHFR
9 neural tube defects 9.9 DHFR MTHFR SLC19A1
10 osteogenic sarcoma 9.9
11 bone mineral density quantitative trait locus 3 9.7
12 ewing sarcoma 9.7
13 osteochondroma 9.7

Graphical network of the top 20 diseases related to Pediatric Osteosarcoma:



Diseases related to Pediatric Osteosarcoma

Symptoms & Phenotypes for Pediatric Osteosarcoma

GenomeRNAi Phenotypes related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.44 MTHFR
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.44 MTHFR
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.44 MTHFR
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.44 DHFR
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.44 MTHFR
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.44 MTHFR
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.44 MTHFR
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.44 DHFR FAS MTHFR
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.44 DHFR MTHFR
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.44 MTHFR

MGI Mouse Phenotypes related to Pediatric Osteosarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.87 DHFR FAS HK2 MTHFR ROCK1 SLC19A1
2 integument MP:0010771 9.73 DHFR FAS MTHFR ROCK1 SLC19A1 SOX4
3 mortality/aging MP:0010768 9.5 DHFR FAS HK2 MTHFR ROCK1 SLC19A1
4 liver/biliary system MP:0005370 9.46 DHFR FAS MTHFR SLC19A1
5 renal/urinary system MP:0005367 8.92 FAS ROCK1 SLC19A1 SOX4

Drugs & Therapeutics for Pediatric Osteosarcoma

Drugs for Pediatric Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 42)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denosumab Approved Phase 2 615258-40-7
2
Cisplatin Approved Phase 2,Not Applicable 15663-27-1 2767 441203 84093
3
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
4
Nivolumab Approved Phase 1, Phase 2 946414-94-4
5 Bone Density Conservation Agents Phase 2
6 Immunoglobulins Phase 2,Phase 1
7 Antibodies Phase 2,Phase 1
8 Pharmaceutical Solutions Phase 2
9 Antibodies, Monoclonal Phase 1, Phase 2
10 Antimetabolites Phase 1, Phase 2,Not Applicable
11 Immunologic Factors Phase 1, Phase 2,Not Applicable
12 Antimetabolites, Antineoplastic Phase 1, Phase 2,Not Applicable
13
Carboplatin Approved Not Applicable 41575-94-4 10339178 38904 498142
14
leucovorin Approved Not Applicable 58-05-9 6006 143
15
Methotrexate Approved Not Applicable 59-05-2, 1959-05-2 126941
16
Mechlorethamine Approved, Investigational Not Applicable 51-75-2 4033
17
Doxorubicin Approved, Investigational Not Applicable 23214-92-8 31703
18
Mesna Approved, Investigational Not Applicable 3375-50-6 598
19
Gemcitabine Approved Not Applicable 95058-81-4 60750
20
Ifosfamide Approved Not Applicable 3778-73-2 3690
21
Folic Acid Approved, Nutraceutical, Vet_approved Not Applicable 59-30-3 6037
22
Doxil Approved June 1999 Not Applicable 31703
23 Vitamin B9 Not Applicable
24 Anti-Infective Agents Not Applicable
25 Protective Agents Not Applicable
26 Antiviral Agents Not Applicable
27 Topoisomerase Inhibitors Not Applicable
28
Isophosphamide mustard Not Applicable 0
29 Anti-Bacterial Agents Not Applicable
30 Vitamin B Complex Not Applicable
31 Nucleic Acid Synthesis Inhibitors Not Applicable
32 Cardiotonic Agents Not Applicable
33 Immunosuppressive Agents Not Applicable
34 Folate Not Applicable
35 Folic Acid Antagonists Not Applicable
36 Alkylating Agents Not Applicable
37 Antimitotic Agents Not Applicable
38 razoxane Not Applicable
39 Antibiotics, Antitubercular Not Applicable
40 Antineoplastic Agents, Alkylating Not Applicable
41 Dermatologic Agents Not Applicable
42 Antirheumatic Agents Not Applicable

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors Recruiting NCT02581384 Phase 1, Phase 2
2 Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma Active, not recruiting NCT02470091 Phase 2
3 Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma Active, not recruiting NCT01650090 Phase 2 Inhaled Lipid Cisplatin (ILC)
4 Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Not yet recruiting NCT03628209 Phase 1, Phase 2 Nivolumab;Azacitidine
5 Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity Recruiting NCT03139318 Not Applicable
6 The Impact of Cancer on the Physical and Psychosocial Well-being Among Childhood Osteosarcoma Survivors Recruiting NCT03298971
7 Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy Terminated NCT00673179 Not Applicable Doxorubicin;Cisplatin;Methotrexate;Leucovorin;Dexrazoxane;Ifosfamide;Gemcitabine;Sargramostim;Mesna

Search NIH Clinical Center for Pediatric Osteosarcoma

Genetic Tests for Pediatric Osteosarcoma

Anatomical Context for Pediatric Osteosarcoma

MalaCards organs/tissues related to Pediatric Osteosarcoma:

41
Bone

Publications for Pediatric Osteosarcoma

Articles related to Pediatric Osteosarcoma:

(show top 50) (show all 103)
# Title Authors Year
1
miRa89188 suppresses tumor progression by targeting SOX4 in pediatric osteosarcoma. ( 29749512 )
2018
2
Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. ( 29357275 )
2018
3
Biological function of microRNA-30c/SOX9 in pediatric osteosarcoma cell growth and metastasis. ( 29364496 )
2018
4
Carbon ion radiotherapy for inoperable pediatric osteosarcoma. ( 29796166 )
2018
5
The Effect of Clown Intervention on Self-Report and Biomarker Measures of Stress and Fatigue in Pediatric Osteosarcoma Inpatients: A Pilot Study. ( 29900751 )
2018
6
Two HLA Class II Gene Variants Are Independently Associated with Pediatric Osteosarcoma Risk. ( 30038050 )
2018
7
Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity. ( 30454696 )
2018
8
Growth of epiphysis after epiphyseal-preservation surgery for childhood osteosarcoma around the knee joint. ( 29875014 )
2018
9
The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma. ( 29889801 )
2018
10
TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma. ( 29163677 )
2017
11
Ambulatory High-dose Methotrexate Administration in Pediatric Osteosarcoma Patients at a Single Institution in Argentina. ( 28937522 )
2017
12
Pediatric Osteosarcoma: An Updated Review. ( 28469335 )
2017
13
Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors. ( 28806574 )
2017
14
The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients. ( 28592186 )
2017
15
Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report. ( 29390436 )
2017
16
The expression and function of miRNA-106 in pediatric osteosarcoma. ( 28272712 )
2017
17
Immunotherapeutic approaches in pediatric osteosarcoma. ( 28353326 )
2017
18
ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma. ( 28267080 )
2017
19
Childhood osteosarcoma: Incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000-2013. ( 28409896 )
2017
20
Downregulated Adhesion-Associated microRNAs as Prognostic Predictors in Childhood Osteosarcoma. ( 28944406 )
2017
21
Pharmacological or genetic inhibition of LDHA reverses tumor progression of pediatric osteosarcoma. ( 27261617 )
2016
22
CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells. ( 26715273 )
2016
23
Multimodality Imaging in Pediatric Osteosarcoma in the Era of Image Gently and Image Wisely Campaign With a Close Look at the CT Scan Radiation Dose. ( 26583624 )
2016
24
Novel insights and therapeutic interventions for pediatric osteosarcoma. ( 27651036 )
2016
25
Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. ( 27104192 )
2016
26
The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. ( 26603261 )
2016
27
Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density. ( 27104175 )
2016
28
Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma. ( 26583357 )
2016
29
Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma. ( 26512351 )
2015
30
PI3K/Akt signaling mediated Hexokinase-2 expression inhibits cell apoptosis and promotes tumor growth in pediatric osteosarcoma. ( 26116768 )
2015
31
Experience of Pediatric Osteosarcoma of the Extremity at a Single Institution in Taiwan: Prognostic Factors and Impact on Survival. ( 25323470 )
2014
32
Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. ( 24038809 )
2014
33
Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. ( 24667129 )
2014
34
In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma. ( 25594070 )
2014
35
Management of local recurrence of pediatric osteosarcoma following limb-sparing surgery. ( 24558066 )
2014
36
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( 25520112 )
2014
37
Pediatric Osteosarcoma: A Single Institution's Experience. ( 25365431 )
2014
38
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. ( 24703847 )
2014
39
Long-term pulmonary function after metastasectomy for childhood osteosarcoma: a report from the St Jude lifetime cohort study. ( 24795268 )
2014
40
Successful management of a childhood osteosarcoma with epiphysiolysis and distraction osteogenesis. ( 25089114 )
2014
41
Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( 23621194 )
2013
42
Bronchioloalveolar carcinoma as a second malignancy in a pediatric osteosarcoma survivor: case report. ( 23758793 )
2013
43
Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. ( 23430441 )
2013
44
Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. ( 24123836 )
2013
45
Combined MicroRNA-340 and ROCK1 mRNA Profiling Predicts Tumor Progression and Prognosis in Pediatric Osteosarcoma. ( 24398981 )
2013
46
Pathological fracture as the presenting feature in pediatric osteosarcoma. ( 23281226 )
2013
47
Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma. ( 22652833 )
2012
48
Correlation of non-mass-like abnormal MR signal intensity with pathological findings surrounding pediatric osteosarcoma and Ewing's sarcoma. ( 22406919 )
2012
49
Plasma proteomic profiling of pediatric osteosarcoma. ( 22083817 )
2012
50
Serum tumor markers in pediatric osteosarcoma: a summary review. ( 22587902 )
2012

Variations for Pediatric Osteosarcoma

Expression for Pediatric Osteosarcoma

Search GEO for disease gene expression data for Pediatric Osteosarcoma.

Pathways for Pediatric Osteosarcoma

Pathways related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.04 DHFR MTHFR SLC19A1
2
Show member pathways
11.67 DHFR MTHFR SLC19A1
3
Show member pathways
11.28 ATIC DHFR MTHFR
4 10.42 ATIC DHFR MTHFR SLC19A1

GO Terms for Pediatric Osteosarcoma

Biological processes related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metabolic process GO:0008152 9.54 ATIC HK2 MTHFR
2 one-carbon metabolic process GO:0006730 9.32 DHFR MTHFR
3 tetrahydrofolate metabolic process GO:0046653 9.26 DHFR MTHFR
4 tetrahydrofolate biosynthetic process GO:0046654 9.16 ATIC DHFR
5 dihydrofolate metabolic process GO:0046452 8.96 ATIC DHFR
6 folic acid metabolic process GO:0046655 8.8 DHFR MTHFR SLC19A1

Molecular functions related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 catalytic activity GO:0003824 9.33 ATIC HK2 MTHFR
2 NADP binding GO:0050661 8.96 DHFR MTHFR
3 folic acid binding GO:0005542 8.62 DHFR SLC19A1

Sources for Pediatric Osteosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....